Industry Briefs: December 17, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: December 17, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

The Court of Appeals for the Federal Circuit has upheld the decision of the District Court, District of Delaware, finding that the US substance patent protecting AstraZeneca’s Crestor (rosuvastatin calcium) (RE37,314 – the ‘314 patent) is valid and enforceable. Read More

Avid Bioservices has completed its biofacility upgrades in response to increased demand for its contract manufacturing, the company says. Read More

Catalent Pharma Solutions and UMN Pharma have formed a collaboration for biosimilar development and production in Japan. Read More

Chemsultants International has added a Class 10,000/Class 1000 cleanroom to its product- and process-development operations. Read More

Cobalt Light Systems has expanded its capacity and relocated into a larger facility in Abingdon, Oxfordshire, United Kingdom. Read More

Elite Pharmaceuticals has formed an agreement for the next year with the company’s sole supplier of the API for Elite’s phentermine product lines that include phentermine HCl tablets (37.5 mg) and phentermine HCl capsules (15 and 30 mg). Read More

Evotec has a license agreement with Janssen Pharmaceuticals regarding its NR2B subtype selective NMDA-antagonist portfolio for development against diseases in the field of depression. Read More

Phenex Pharmaceuticals and Janssen Biotech have formed a research collaboration and license agreement for autoimmune and chronic inflammatory disorders. Read More

Sartorius Stedim Biotech has formed a sales partnership with Umetrics to expand its process analytical technology software portfolio for the optimization of biopharmaceutical development and manufacturing processes. Read More

People News

Amgen has named CEO Robert A. Bradway chairman of its board of directors. Read More

Impax Laboratories has appointed Bryan M. Reasons as senior vice-president and chief financial officer. Read More

Sanofi has announced that Hanspeter Spek, president, global operations, will retire from his current role in mid-2013. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here